Bruton's TK inhibitors: Structural insights and evolution of clinical candidates

Future Medicinal Chemistry

Volumn 6, Issue 6, 2014, Pages 675-695

  Xing, Li ^a   Huang, Adrian ^b  

^a PFIZER INC   (United States)

^b WELLESLEY COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE INHIBITOR; CC 292; CGI 1746; DASATINIB; FOSTAMATINIB; IBRUTINIB; LIGAND; RN 486; UNCLASSIFIED DRUG; AGAMMAGLOBULINAEMIA TYROSINE KINASE; MOLECULAR LIBRARY; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CHEMICAL STRUCTURE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); CONFORMATION; CRYSTAL STRUCTURE; DRUG APPROVAL; DRUG SAFETY; DRUG STRUCTURE; HUMAN; MANTLE CELL LYMPHOMA; NONHUMAN; ONCOLOGY; PRIORITY JOURNAL; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; CHEMISTRY; DRUG DEVELOPMENT; ENZYMOLOGY; METABOLISM; MOLECULAR LIBRARY; NEOPLASMS; PHARMACOLOGY; PROTEIN CONFORMATION; THERAPEUTIC USE; X RAY CRYSTALLOGRAPHY;

ANIMALS; AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; NEOPLASMS; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; SMALL MOLECULE LIBRARIES;

EID: 84902082846     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.24     Document Type: Review

References (119)

1. Lindvall JM, Blomberg KE, Valiaho J et al. Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol. Rev. 203, 200-215 (2005).
2. Uckun FM, Qazi S. Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity. Expert Opin. Ther. Pat. 20(11), 1457-1470 (2010).
3. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat. Rev. Immunol. 6(5), 394-403 (2006).
4. Maas A, Hendriks RW. Role of Bruton's tyrosine kinase in B cell development. Dev. Immunol. 8(3-4), 171-181 (2001).
5. Qiu Y, Kung HJ. Signaling network of the Btk family kinases. Oncogene 19(49), 5651-5661 (2000).
6. Kurosaki T, Hikida M. Tyrosine kinases and their substrates in B lymphocytes. Immunol. Rev. 228(1), 132-148 (2009).
7. Mohamed AJ, Yu L, Backesjo CM et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol. Rev. 228(1), 58-73 (2009).
8. Baba Y, Hashimoto S, Matsushita M et al. BLNK mediates Syk-dependent Btk activation. Proc. Natl Acad. Sci. USA 98(5), 2582-2586 (2001).
9. Irish JM, Czerwinski DK, Nolan GP, Levy R. Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood 108(9), 3135-3142 (2006).
10. Jumaa H, Hendriks RW, Reth M. B cell signaling and tumorigenesis. Ann. Rev. Immunol. 23, 415-445 (2005).
11. Tsukada S, Saffran DC, Rawlings DJ et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72(2), 279-290 (1993).
12. Vetrie D, Vorechovsky I, Sideras P et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 361(6409), 226-233 (1993).
13. Rawlings DJ, Saffran DC, Tsukada S et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 261(5119), 358-361 (1993).
14. Thomas JD, Sideras P, Smith CI, Vorechovsky I, Chapman V, Paul WE. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes. Science 261(5119), 355-358 (1993).
15. Conley ME. B cells in patients with X-linked agammaglobulinemia. J. Immunol. 134(5), 3070-3074 (1985).
16. Leandro MJ, De La Torre I. Translational mini-review series on B cell-directed therapies: the pathogenic role of B cells in autoantibody- associated autoimmune diseases-lessons from B cell-depletion therapy. Clin. Exp. Immunol. 157(2), 191-197 (2009).
17. Teng YK, Huizinga TW, Van Laar JM. Targeted therapies in rheumatoid arthritis: Focus on rituximab. Biologics 1(4), 325-333 (2007).
18. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350(25), 2572-2581 (2004).
19. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 40(2), 205-211 (2001).
20. Hendriks RW. Drug discovery: New Btk inhibitor holds promise. Nat. Chem. Biol. 7(1), 4-5 (2011).
21. Di Paolo JA, Huang T, Balazs M ,Specific Btk inhibition suppresses B cell-and myeloid cell-mediated arthritis. Nat. Chem. Biol. 7(1), 41-50 (2011).
22. Honigberg LA, Smith AM, Sirisawad M ,The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107(29), 13075-13080 (2010).
23. Pan Z, Scheerens H, Li SJ et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem 2(1), 58-61 (2007).
24. Singh J, Petter RC, Kluge AF. Targeted covalent drugs of the kinase family. Curr. Opin. Chem. Biol. 14(4), 475-480 (2010).
25. Chang BY, Huang MM, Francesco M et al. The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells. Arthritis Res. Ther. 13(4), R115 (2011).
26. Pharmacyclics Inc.: full prescribing information for IMBRUVICA™. www.imbruvica.com/downloads/Prescribing-Information.pdf
27. Advani RH, Buggy JJ, Sharman JP et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J.Clin. Oncol. 31(1), 88-94 (2013).
28. Harrison C. Trial watch: BTK inhibitor shows positive results in B cell malignancies. Nat. Rev. Drug Discov. 11(2), 96 (2012).
29. Evans EK, Tester R, Aslanian S et al. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J. Pharm. Exp. Ther. 346(2), 219-228 (2013).
30. Hantschel O, Rix U, Schmidt U et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc. Natl Acad. Sci. USA 104(33), 13283-13288 (2007).
31. Davis RE, Ngo VN, Lenz G et al. Chronic active B-cellreceptor signalling in diffuse large B-cell lymphoma. Nature 463(7277), 88-92 (2010).
32. Dar AC, Shokat KM. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Ann. Rev. Biochem. 80, 769-795
33. Alton GR, Lunney EA. Targeting the unactivated conformations of protein kinases for small molecule drug discovery. Expert Opin. Drug Discov. 3(6), 595-605 (2008).
34. Nagar B, Bornmann WG, Pellicena P et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62(15), 4236-4243 (2002).
35. Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116(6), 855-867 (2004).
36. Wood ER, Truesdale AT, Mcdonald OB et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64(18), 6652-6659 (2004).
37. Mao C, Zhou M, Uckun FM. Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia. J. Biol. Chem. 276(44), 41435-41443 (2001).
38. Marcotte DJ, Liu YT, Arduini RM et al. Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Sci. 19(3), 429-439 (2010).
39. Kuglstatter A, Wong A, Tsing S et al. Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures. Protein Sci. 20(2), 428-436 (2011).
40. Goldberg J, Nairn AC, Kuriyan J. Structural basis for the autoinhibition of calcium/calmodulin-dependent protein kinase I. Cell 84(6), 875-887 (1996).
41. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cell 3(5), 629-638 (1999).
42. Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J. Crystal structure of Hck in complex with a Src familyselective tyrosine kinase inhibitor. Mol. Cell 3(5), 639-648 (1999).
43. Kutach AK, Villasenor AG, Lam D et al. Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation. Chem. Biol. Drug Des. 76(2), 154-163 (2010).
44. Lou Y, Owens TD, Kuglstatter A, Kondru RK, Goldstein DM. Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J. Med. Chem. 55(10), 4539-4550 (2012).
45. Farenc C, Celie PH, Tensen CP, De Esch IJ, Siegal G. Crystal structure of the EphA4 protein tyrosine kinase domain in the apo-and dasatinib-bound state. FEBS Lett. 585(22), 3593-3599 (2011).
46. Williams NK, Lucet IS, Klinken SP, Ingley E, Rossjohn J. Crystal structures of the Lyn protein tyrosine kinase domain in its Apo-and inhibitor-bound state. J. Biol. Chem. 284(1), 284-291 (2009).
47. Muckelbauer J, Sack JS, Ahmed N et al. X-ray crystal structure of bone marrow kinase in the x chromosome: a Tec family kinase. Chem. Biol. Drug Des. 78(5), 739-748 (2011).
48. Getlik M, Grutter C, Simard JR et al. Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. J. Med. Chem. 52(13), 3915-3926 (2009).
49. Tokarski JS, Newitt JA, Chang CY et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinibresistant ABL mutants. Cancer Res. 66(11), 5790-5797 (2006).
50. Cowan-Jacob SW, Fendrich G, Manley PW et al. The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation. Structure 13(6), 861-871 (2005).
51. Goldstein DM, Alfredson T, Bertrand J et al. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl] me thanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase. J. Med. Chem. 49(5), 1562-1575 (2006).
52. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 363(14), 1303-1312 (2010).
53. Rigel Pharmaceuticals, Inc.: fostamatinib update following end-of-Phase II meeting with US FDA. www.rigel.com/rigel/ITP
54. Sweeny DJ, Li W, Clough J et al. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab. Dispos. 38(7), 1166-1176 (2010).
55. Norman P. A novel Syk kinase inhibitor suitable for inhalation: R-343()-WO-2009031011. Expert Opin. Ther. Pat. 19(10), 1469-1472 (2009).
56. Villasenor AG, Kondru R, Ho H et al. Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes. Chem. Biol. Drug Des. 73(4), 466-470 (2009).
57. Shan Y, Arkhipov A, Kim ET, Pan AC, Shaw DE. Transitions to catalytically inactive conformations in EGFR kinase. Proc. Natl Acad. Sci. USA 110(18), 7270-7275 (2013).
58. Regan J, Pargellis CA, Cirillo PF et al. The kinetics of binding to p38MAP kinase by analogues of BIRB 796. Bioorg. Med. Chem. Lett. 13(18), 3101-3104 (2003).
59. Pargellis C, Tong L, Churchill L et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat. Struct. Biol. 9(4), 268-272 (2002).
60. Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem. Biol. 12(6), 621-637 (2005).
61. Zhang R, Monsma F. Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs. Expert Opin. Drug Discov. 5(11), 1023-1029 (2010).
62. Mclean LR, Zhang Y, Zaidi N et al. X-ray crystallographic structure-based design of selective thienopyrazole inhibitors for interleukin-2-inducible tyrosine kinase. Bioorg. Med. Chem. Lett. 22(9), 3296-3300 (2012).
63. Charrier JD, Miller A, Kay DP et al. Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors. J. Med. Chem. 54(7), 2341-2350 (2011).
64. Brown K, Long JM, Vial SC et al. Crystal structures of interleukin-2 tyrosine kinase and their implications for the design of selective inhibitors. J. Biol. Chem. 279(18), 18727-18732 (2004).
65. Mahajan S, Ghosh S, Sudbeck EA et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-betahydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J. Biol. Chem. 274(14), 9587-9599 (1999).
66. Van Den Akker E, Van Dijk TB, Schmidt U et al. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biol. Chem. 385(5), 409-413 (2004).
67. Uckun FM, Dibirdik I, Qazi S et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK). Bioorg. Med. Chem. 15(2), 800-814 (2007).
68. Uckun FM, Tibbles HE, Vassilev AO. Bruton's tyrosine kinase as a new therapeutic target. Anti-Cancer Agents Med. Chem. 7(6), 624-632 (2007).
69. Leproult E, Barluenga S, Moras D, Wurtz JM, Winssinger N. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors. J. Med. Chem. 54(5), 1347-1355 (2011).
70. Cohen MS, Zhang C, Shokat KM, Taunton J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308(5726), 1318-1321 (2005).
71. Burstein HJ, Sun Y, Dirix LY et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J.Clin. Oncol. 28(8), 1301-1307 (2010).
72. Liu L, Di Paolo JA, Barbosa J, Rong H, Reif K, Wong H. Antiarthritis effect of a novel bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanismbased pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. J. Pharm. Exp. Ther. 338(1), 154-163 (2011).
73. Liu L, Halladay JS, Shin Y et al. Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor. Drug Metab. Dispos. 39(1), 1840-1849 (2011).
74. Xu D, Kim Y, Postelnek J ,RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J. Pharm. Exp. Ther. 341(1), 90-103 (2012).
75. Honigberg LA, Smith AM, Sirisawad M et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107, 13075-13080 (2010).
76. Chang BY, Thiemann P, Francesco M et al. PCI-45292, a novel Btk Inhibitor with optimized pharmaceutical properties, demonstrates potent activities in mouse models of arthritis. Arthritis Rheum. 62(Suppl. 10), 286 (2010).
77. Advani RH, Buggy JJ, Sharman JP et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J.Clin. Oncol. 31(1), 88-94 (2013).
78. Advani R, Sharman JP, Smith SM et al. Effect of BTK inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: Evidence of antitumor activity from a Phase I study. J.Clin. Oncol. 28 (Suppl. 15), 8012 (2010).
79. Pollyea DA, Smith S, Fowler N . A Phase I dose escalation study of the BTK inhibitor PCI-32765 in relapsed and refractory B cell non-hodgkin lymphoma and use of a novel fluorescent probe pharmacodynamic assay. Presented at: 51st ASH Annual Meeting and Exposition. LA, USA, 5-8 December 2010.
80. Byrd JC, Furman RR, Coutre SE et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369(1), 32-42 (2013).
81. Evans EK, Tester R, Aslanian S et al. Inhibition of BTK with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J. Pharm. Exp. Ther. 346(2), 219-228 (2013).
82. Brown J, Harb W, Sharman J . Phase 1 study of single agent CC-292, a highly selective Bruton's tyrosine kinase (BTK) inhibitor, in relapsed/refractory chronic lymphocytic leukemia (CLL) and B-cell non-hodgkin lymphoma (BNHL). Presented at: 18th Annual Congress of the European Hematology Association. Stockholm, Sweden,13-16 June 2013.
83. Yoshizawa T, Ariza Y, Ueda Y, Hotta S, Narita M, Kawabata K. Development of Bruton's tyrosine kinase (BTK) inhibitor, ONO-4059: efficacy in a collagen induced arthritis (CIA) model indicates potential treatment for rheumatoid arthritis (RA). Arthritis Rheum. 64 (Suppl. 10), 1660 (2012).
84. CGI Pharmaceuticals, Inc.: WO2005005429 (2005).
85. CGI Pharmaceuticals, Inc.: WO2005014599 (2005).
86. CGI Pharmaceuticals, Inc.: WO2005047290 (2005).
87. Gilead Connecticut, Inc.; Genentech, Inc.: WO2012030990 (2012).
88. Gilead Connecticut, Inc.; Genentech, Inc.: WO2012031004 (2012).
89. Genentech, Inc.: WO2013067260 (2013).
90. Genentech, Inc.: WO2013067274 (2013).
91. Genentech, Inc.: WO2013067277 (2013).
92. Roche Palo Alto LLC: US20090105209 (2009).
93. Roche Palo Alto LLC: WO2009077334 (2009).
94. Roche Palo Alto LLC: US20090306041 (2009).
95. Roche Palo Alto LLC: WO2010006947 (2010).
96. Roche Palo Alto LLC: WO2010122038 (2010).
97. F. Hoffmann-La Roche Ag.: US20100222325 (2010).
98. Roche Palo Alto LLC: WO2010000633 (2010).
99. F. Hoffmann-La Roche Ag.: WO2012020008 (2012).
100. F. Hoffmann-La Roche Ag.: WO2012156334 (2012).
101. F. Hoffmann-La Roche Ag.: WO2013083666 (2013).
102. Kremer JM, Bloom BJ, Breedveld FC et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 60(7), 1895-1905 (2009).
103. Bristol-Myers Squibb Company: WO2008116064 (2008).
104. Bristol-Myers Squibb Company: WO2010011837 (2010).
105. Bristol-Myers Squibb Company: WO2010160303 (2010).
106. Bristol-Myers Squibb Company: WO2011159857 (2011).
107. Bristol-Myers Squibb Company: WO2011019780 (2011).
108. Biogen Idec Ma Inc.; Sunesis Pharmaceuticals, Inc.: WO2011029043 (2011).
109. Biogen Idec Ma Inc.; Sunesis Pharmaceuticals, Inc.: WO2011029046 (2011).
110. Merck Sharp & Dohme Corp.: WO2013010380 (2013).
111. Wang ML, Rule S, Martin P et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369(6), 507-516 (2013).
112. Pharmacyclics Inc.: news release. http://ir.pharmacyclics. com/releasedetail.cfmReleaseID=807003
113. Pharmacyclics, Inc.: US20100254905 (2010).
114. Kim KH, Maderna A, Schnute ME et al.: Imidazo 1,5-a quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis. Bioorg. Med. Chem. Lett. 21(21), 6258-6263 (2011).
115. Locus Pharmaceuticals, Inc.: WO2010126960 (2010).
116. University of Utah Research Foundation: WO2012135801 (2012).
117. ClinicalTrials.gov: NCT01659255. www.clinicaltrials.gov/show/NCT01659255
118. Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10(4), 307-317 (2011).
119. Potashman MH, Duggan ME. Covalent modifiers: an orthogonal approach to drug design. J. Med. Chem. 52(5), 1231-1246 (2009).